ATE370137T1 - 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren - Google Patents

4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren

Info

Publication number
ATE370137T1
ATE370137T1 AT02783059T AT02783059T ATE370137T1 AT E370137 T1 ATE370137 T1 AT E370137T1 AT 02783059 T AT02783059 T AT 02783059T AT 02783059 T AT02783059 T AT 02783059T AT E370137 T1 ATE370137 T1 AT E370137T1
Authority
AT
Austria
Prior art keywords
membed
heteroaryl
acyl
pyrrolidine derivatives
hcv inhibitors
Prior art date
Application number
AT02783059T
Other languages
German (de)
English (en)
Inventor
Gianpaolo Bravi
Rossella Guidetti
David Haigh
Charles David Hartley
Peter David Howes
Deborah Lynette Jackson
Victoria Lucy Helen Lovegrove
Pritom Shah
Martin John Slater
Katrina Jane Wareing
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0126440A external-priority patent/GB0126440D0/en
Priority claimed from GB0203900A external-priority patent/GB0203900D0/en
Priority claimed from GB0219321A external-priority patent/GB0219321D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE370137T1 publication Critical patent/ATE370137T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02783059T 2001-11-02 2002-10-30 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren ATE370137T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0126440A GB0126440D0 (en) 2001-11-02 2001-11-02 Compounds
GB0203900A GB0203900D0 (en) 2002-02-19 2002-02-19 Compounds
GB0219321A GB0219321D0 (en) 2002-08-19 2002-08-19 Compounds

Publications (1)

Publication Number Publication Date
ATE370137T1 true ATE370137T1 (de) 2007-09-15

Family

ID=27256312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02783059T ATE370137T1 (de) 2001-11-02 2002-10-30 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren

Country Status (9)

Country Link
US (1) US7259163B2 (enExample)
EP (1) EP1440069B1 (enExample)
JP (1) JP2005515172A (enExample)
AR (1) AR037182A1 (enExample)
AT (1) ATE370137T1 (enExample)
DE (1) DE60221875T2 (enExample)
ES (1) ES2289161T3 (enExample)
TW (1) TW200302823A (enExample)
WO (1) WO2003037895A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211418D0 (en) * 2002-05-17 2002-06-26 Glaxo Group Ltd Compounds
EP2033654B1 (en) 2003-04-16 2012-05-16 Bristol-Myers Squibb Company Process for resolving a mixture of alkyl ester enantiomers using an enzyme
SG184700A1 (en) 2004-02-20 2012-10-30 Boehringer Ingelheim Int Viral polymerase inhibitors
JP2007530516A (ja) * 2004-03-26 2007-11-01 スミスクライン・ビーチャム・コーポレイション 抗ウイルス剤として有用な４−カルボキシピラゾール誘導体
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
WO2007039146A1 (en) * 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090004140A1 (en) * 2007-06-26 2009-01-01 Yao-Ling Qiu 4-substituted pyrrolidine as anti-infectives
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0922366B8 (pt) 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc composto, composição farmacêutica e uso de um composto
SG171890A1 (en) 2008-12-03 2011-07-28 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
CN102695513A (zh) 2008-12-23 2012-09-26 吉利德制药有限责任公司 核苷氨基磷酸酯
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc FUSIONED CORE INHIBITORS OF HEPATITIS C
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
ES2655091T3 (es) 2009-12-18 2018-02-16 Ogeda Sa Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
WO2012020036A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
BR112013009789A2 (pt) 2010-10-26 2016-07-19 Presidio Pharmaceuticals Inc inibidores do vírus da hepatite c
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
BR112014008616A2 (pt) 2011-10-10 2017-04-18 Hoffmann La Roche compostos antivirais
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES2564906T3 (es) 2011-12-16 2016-03-29 F. Hoffmann-La Roche Ag Inhibidores de NS5A del VHC
AU2012357986B2 (en) 2011-12-20 2017-02-02 Riboscience Llc 4'-Azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
EP2794629B1 (en) 2011-12-20 2017-05-24 Riboscience LLC 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
KR20140130449A (ko) 2012-02-24 2014-11-10 에프. 호프만-라 로슈 아게 항바이러스 화합물
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
CN105073726B (zh) 2013-01-23 2017-05-31 弗·哈夫曼-拉罗切有限公司 抗病毒三唑衍生物
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
CN105008350B (zh) 2013-03-05 2018-05-08 弗·哈夫曼-拉罗切有限公司 抗病毒化合物
MA38678A1 (fr) 2013-05-16 2017-07-31 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
US9895442B2 (en) 2013-05-16 2018-02-20 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
KR102259934B1 (ko) 2013-11-27 2021-06-03 에픽스 테라퓨틱스 염증 질환의 치료에 사용되기 위한 화합물, 의약 조성물 및 방법
CN111194217B (zh) 2017-09-21 2024-01-12 里伯赛恩斯有限责任公司 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
CN109678814B (zh) * 2018-12-28 2021-03-23 浙江外国语学院 一种制备2-氯-1, 3-噻唑-5-甲醛的方法
JP2023529867A (ja) 2020-06-05 2023-07-12 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395007B (de) * 1990-03-29 1992-08-25 Noe Christian Modifizierte cyclische aminosaeuren und aus diesen synthetisierte dipeptide und verfahren zu ihrer herstellung
AU3761393A (en) 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
US6455571B1 (en) 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
HUP0101224A3 (en) 1998-04-23 2002-12-28 Abbott Lab Pyrrolidine derivatives as inhibitors of neuraminidases and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
US7259163B2 (en) 2007-08-21
DE60221875T2 (de) 2007-12-20
EP1440069A1 (en) 2004-07-28
ES2289161T3 (es) 2008-02-01
WO2003037895A1 (en) 2003-05-08
DE60221875D1 (de) 2007-09-27
EP1440069B1 (en) 2007-08-15
US20050043390A1 (en) 2005-02-24
AR037182A1 (es) 2004-10-27
TW200302823A (en) 2003-08-16
JP2005515172A (ja) 2005-05-26

Similar Documents

Publication Publication Date Title
ATE370137T1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
ATE416171T1 (de) 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
DE60305061D1 (de) 2-pyridonderivate als inhibitoren von neutrophiler elastase
DE60317466D1 (de) Nicotinamid-derivate als pde4-hemmer
NO20041293L (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
DK1505963T3 (da) Hepatitis C-inhibitorer
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DK1458685T3 (da) Substituerede phenylderivater
ATE368651T1 (de) Pyridazinon-derivate als gsk-3beta-hemmer
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
ATE278690T1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
DE60328978D1 (de) Isochinolinderivate als mao-b inhibitoren
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
DE60231897D1 (de) Triazol derivate als cyclooxygenase inhibitoren
ATE308325T1 (de) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties